At #JPM23, another rare disease buyout as Ipsen acquires Albireo for $952M

Be­fore most JP­Mers arose Mon­day morn­ing, Ipsen an­nounced that it is buy­ing rare dis­ease biotech Al­bireo Phar­ma. That’s the sec­ond deal dis­closed Mon­day morn­ing, along with As­traZeneca grab­bing car­dio­vas­cu­lar up­start Cin­Cor Phar­ma. With the Chiesi-Am­ryt rare dis­ease deal…#cholestatic #roncooper #medicines #albireo #arena #epizyme #vielabio #albo #expanded #into2024
Source: Reuters: Health - Category: Consumer Health News Source Type: news